Seeking Alpha

Seatle Genetics (SGEN +1.5%) moves up today after saying it's initiated its Phase II clinical...

Seatle Genetics (SGEN +1.5%) moves up today after saying it's initiated its Phase II clinical trial for Adcertris, a drug candidate to be used as a front-line therapy for patients age 60 or older with newly diagnosed Hodgkin lymphoma.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs